Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufacturing organization (CDMO) business from its biosimilar and novel drug development business, currently undertaken by its wholly owned Samsung Bioepis Co. Source: The Korea Economic Daily 22/5/2025